Aptamers: An emerging class of therapeutics

Annual Review of Medicine

Volumn 56, Issue , 2005, Pages 555-583

  Nimjee, Shahid M ^a   Rusconi, Christopher P ^a,b   Sullenger, Bruce A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Regado Biosciences Inc   (United States)

Author keywords

Antidote; RNA ligand; SELEX; Therapeutic target

Indexed keywords

2' FLUOROPYRIMIDINE APTAMER; 2' O METHYLPURINE APTAMER; ANTIBODY; ANTICOAGULANT AGENT; ANTIDOTE; APTAMER; BLOOD CLOTTING FACTOR 9A APTAMER; DNA APTAMER; ED 45; HEPARIN; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN DNA APTAMER; L SELECTIN IMMUNOGLOBULIN G FUSION PROTEIN; LD 174; LD 196; LD 201; LEUKOCYTE ELASTASE APTAMER; LIGAND; NUCLEIC ACID LIGAND; NX 21909; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR B APTAMER; RNA LIGAND; SIALYL LEWIS X APTAMER; TAT APTAMER; TRANSACTIVATION RESPONSE DECOY; TRANSCRIPTION FACTOR E2F DECOY; TRANSFER RNA REV RESPONSE ELEMENT APTAMER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN APTAMER;

BINDING AFFINITY; BLEEDING; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG ISOLATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; TRANSACTIVATION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIDOTES; APTAMERS, NUCLEOTIDE; BACTERIAL PROTEINS; CLINICAL TRIALS, PHASE III; DNA-BINDING PROTEINS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; GENE LIBRARY; HIV INFECTIONS; HUMANS; OLIGONUCLEOTIDES; TRANSCRIPTION FACTORS; VIRAL PROTEINS;

EID: 14544295783     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.062904.144915     Document Type: Review

References (100)

1. Cullen BR, Greene WC. 1989. Regulatory pathways governing HIV-1 replication. Cell 58:423-26
2. Marciniak RA, Garcia-Blanco MA, Sharp PA. 1990. Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 87:3624-28
3. Burgert HG, Ruzsics Z, Obermeier S, et al. 2002. Subversion of host defense mechanisms by adenoviruses. Curr. Top. Microbiol. Immunol. 269:273-318
4. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. 1990. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-8
5. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. 1991. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol 65:6811-16
6. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-10
7. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-22
8. Doudna JA, Cech TR, Sullenger BA. 1995. Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc. Natl. Acad. Sci. USA 92:2355-59
9. Lee SW, Sullenger BA. 1997. Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat. Biotechnol. 15:41-5
10. Rusconi CP, Scardino E, Layzer J, et al. 2002. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90-94
11. Rusconi CP, Yeh A, Lyerly HK, et al. 2000. Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb. Haemostasis 84:841-48
12. Eyetech Study Group. 2002. Preclinical and phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143-52
13. Eyetech Study Group. 2003. Antivascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110:979-86
14. Jellinek D, Green LS, Bell C, et al. 1995. Potent 2́-amino- 2́-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34:11363-72
15. Willis MC, Collins BD, Zhang T, et al. 1998. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. 9:573-82; erratum, 9:633
16. Beigelman L, McSwiggen JA, Draper KG, et al. 1995. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J. Biol. Chem. 270:25702-8
17. Tucker CE, Chen LS, Judkins MB, et al. 1999. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J. Chromatogr. B Biomed. Sci. Appl. 732:203-12
18. White R, Rusconi C, Scardino E, et al. 2001. Generation of species cross-reactive aptamers using "toggle" SELEX. Mol. Ther. 4:567-73
19. Yamamoto R, Katahira M, Nishikawa S, et al. 2000. A novel RNA motif that binds efficiently and specifically to the Tat protein of HIV and inhibits the transactivation by Tat of transcription in vitro and in vivo. Genes Cells 5:371-88
20. Browning CM, Cagnon L, Good PD, et al. 1999. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 Tat activation-response RNA decoy. J. Virol. 73:5191-95
21. Lee TC, Sullenger BA, Gallardo HF, et al. 1992. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol. 4:66-74
22. + cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94:368-71
23. Tuerk C, MacDougal S, Gold L. 1992. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 89: 6988-92
24. Joshi P, Prasad VR. 2002. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J. Virol. 76:6545-57
25. Kumar PK, Machida K, Urvil PT, et al. 1997. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237:270-82
26. Fukuda K, Vishnuvardhan D, Sekiya S, et al. 2000. Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur. J. Biochem. 267:3685-94
27. Ulrich H, Magdesian MH, Alves MJ, Colli W. 2002. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J. Biol. Chem. 277:20756-62
28. Sc formation. ChemBioChem 3: 717-25
29. Coughlin SR. 2000. Thrombin signalling and protease-activated receptors. Nature 407:258-64
30. Bock LC, Griffin LC, Latham JA, et al. 1992. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355:564-66
31. Griffin LC, Tidmarsh GF, Bock LC, et al. 1993. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81:3271-76
32. DeAnda A Jr, Coutre SE, Moon MR, et al. 1994. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. Ann. Thorac. Surg. 58:344-50
33. Schmidt AE, Bajaj SP. 2003. Structure-function relationships in Factor IX and Factor IXa. Trends Cardiovasc. Med. 13:39-45
34. Ginsberg JA, Crowther MA, White RH, Ortel TL. 2001. Anticoagulation therapy. Hematology:339-51
35. Blakeman B. 1999. Management of heparin-induced thrombocytopenia: a cardiovascular surgeon's perspective. Semin. Hematol. 36:37-41
36. Rosen LS. 2002. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9:36-44
37. Adamis AP, Miller JW, Bernal MT, et al. 1994. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:445-50
38. Pierce EA, Avery RL, Foley ED, et al. 1995. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA 92:905-9
39. Kvanta A, Algvere PV, Berglin L, Seregard S. 1996. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Visual Sci. 37:1929-34
40. Ruckman J, Green LS, Beeson J, et al. 1998. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 273:20556-67
41. Puliafito C. 2003. The anti-VEGF aptamer approach: the Macugen collaborative trial. Presented at Am. Acad. Ophthalmol. Meet., Anaheim, CA
42. Holash J, Maisonpierre PC, Compton D, et al. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-98
43. White RR, Shan S, Rusconi CP, et al. 2003. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Natl. Acad. Sci. USA 100:5028-33
44. Doring G. 1994. The role of neutrophil elastase in chronic inflammation. Am. J. Resp. Crit. Care Med. 150:8114-17
45. Smith D, Kirschenheuter GP, Charlton J, et al. 1995. In vitro selection of RNA-based irreversible inhibitors of human neutrophil elastase. Chem. Biol. 2:741-50
46. Charlton J, Kirschenheuter GP, Smith D. 1997. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry 36:3018-26
47. Bless NM, Smith D, Charlton J, et al. 1997. Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury. Curr. Biol. 7:877-80
48. Heldin CH. 1992. Structural and functional studies on platelet-derived growth factor. EMBO J. 11:4251-59
49. Lindner V, Giachelli CM, Schwartz SM, Reidy MA. 1995. A subpopulation of smooth muscle cells in injured rat arteries expresses platelet-derived growth factor-B chain mRNA. Circ. Res. 76:951-57
50. Iida H, Seifert R, Alpers CE, et al. 1991. Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc. Natl. Acad. Sci. USA 88:6560-64
51. Green LS, Jellinek D, Jenison R, et al. 1996. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35:14413-24
52. Floege J, Ostendorf T, Janssen U, et al. 1999. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol. 154:169-79
53. Ostendorf T, Kunter U, Grone HJ, et al. 2001. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 12:909-18
54. Ostendorf T, Kunter U, van Roeyen C, et al. 2002. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J. Am. Soc. Nephrol. 13:658-67
55. Jain RK. 1987. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47:3039-51
56. Jain RK. 1996. Delivery of molecular medicine to solid tumors. Science 271:1079-80
57. Pietras K, Ostman A, Sjoquist M, et al. 2001. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61:2929-34
58. Bevilacqua MP, Nelson RM. 1993. Selectins. J. Clin. Invest. 91:379-87
59. Jenison RD, Jennings SD, Walker DW, et al. 1998. Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev. 8:265-79
60. O'Connell D, Koenig A, Jennings S, et al. 1996. Calcium-dependent oligonucleotide antagonists specific for L-selectin. PNAS 93:5883-87
61. Watson SR, Chang YF, O'Connell D, et al. 2000. Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev. 10:63-75
62. Hicke BJ, Marion C, Chang YF, et al. 2001. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276:48644-54
63. Jeong S, Eom T, Kim S, et al. 2001. In vitro selection of the RNA aptamer against the Sialyl Lewis X and its inhibition of the cell adhesion. Biochem. Biophys. Res. Commun. 281:237-43
64. Rintala EM, Nevalainen TJ. 1993. Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections. Clin. Infect. Dis. 17:864-70
65. Bridonneau P, Chang YF, O'Connell D, et al. 1998. High-affinity aptamers selectively inhibit human nonpancreatic secretory phospholipase A2 (hnps-PLA2). J. Med. Chem. 41:778-86
66. Verma IM, Stevenson JK, Schwarz EM, et al. 1995. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 9:2723-35
67. Beg AA, Baltimore D. 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274:782-84
68. Morishita R, Sugimoto T, Aoki M, et al. 1997. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat. Med. 3:894-99
69. Sawa Y, Morishita R, Suzuki K, et al. 1997. A novel strategy for myocardial protection using in vivo transfection of cis element "decoy" against NFkappaB binding site: evidence for a role of NFkappaB in ischemia-reperfusion injury. Circulation 96:11-280-84
70. Tomita N, Morishita R, Tomita S, et al. 2000. Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. Gene Ther. 7:1326-32
71. Ueno T, Sawa Y, Kitagawa-Sakakida S, et al. 2001. Nuclear factor-κB decoy attenuates neuronal damage after global brain ischemia: a future strategy for brain protection during circulatory arrest. J. Thorac. Cardiovasc. Surg. 122:720-27
72. Morgan B. 1995. Physiology and pathophysiology of complement: progress and trends. Crit. Rev. Clin. Lab. Sci. 32:165-98
73. Mulligan M, Schmid E, Till G, et al. 1997. C5a-dependent up-regulation in vivo of lung vascular P-selectin. J. Immunol 158:1857-61
74. Biesecker G, Dihel L, Enney K, Bendele RA. 1999. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 42:219-30
75. Hunter T. 1993. Braking the cycle. Cell 75:839-41
76. Nevins JR. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-29
77. Hiebert SW, Lipp M, Kevins JR. 1989. E1A-dependenttrans-activation of the human MYC promoter is mediated by the E2F factor. Proc. Natl. Acad. Sci. USA 86:3594-98
78. Morishita R, Gibbons GH, Horiuchi M, et al. 1995. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 92:5855-59
79. Mann MJ, Gibbons GH, Hutchinson H, et al. 1999. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc. Natl. Acad. Sci. USA 96:6411-16
80. Mann MJ, Whittemore AD, Donaldson MC, et al. 1999. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354: 1493-98
81. Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ. 2001. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J. Thorac. Cardiovasc. Surg. 121: 714-22
82. Ishizaki J, Nevins JR, Sullenger BA. 1996. Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nat. Med. 2:1386-89
83. Tasch J, Gong M, Sadelain M, Heston WDW. 2001. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy. Crit. Rev. Immunol. 21:249-61
84. Lupold SE, Hicke BJ, Lin Y, Coffey DS. 2002. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62:4029-33
85. Huang J, Moore J, Soffer S, et al. 2001. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J. Pediatr. Surg. 36:357-61
86. Kim ES, Serur A, Huang J, et al. 2002. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. USA 99: 11399-404
87. Erickson HP, Bourdon MA. 1989. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu. Rev. Cell Biol. 5:71-92
88. Hicke BJ, Stephens AW. 2000. Escort aptamers: a delivery service for diagnosis and therapy. J. Clin. Invest. 106:923-28
89. Zhang B, Roth R. 1991. A region of the insulin receptor important for ligand binding (residues 450-601) is recognized by patients' autoimmune antibodies and inhibitory monoclonal antibodies. Proc. Natl. Acad. Sci. USA 88:9858-62
90. Lee SW, Sullenger BA. 1996. Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J. Exp. Med. 184:315-24
91. Drachman DB. 1994. Myasthenia gravis. N. Engl. J. Med. 330:1797-810
92. Seo H-S, Lee S-W. 2000. In vitro selection of the 2′-fluoro- 2′-deoxyribonucleotide decoy RNA inhibitor of myasthenia autoantibodies. J. Microbiol. Biotechnol. 10:7070-13
93. Gounni AS, Lamkhioued B, Ochiai K, et al. 1994. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 367:183-86
94. Sutton BJ, Gould HJ. 1993. The human IgE network. Nature 366:421-28
95. Wiegand T, Williams P, Dreskin S, et al. 1996. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J. Immunol. 157:221-30
96. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. 1990. The LEA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144:4579-86
97. Kubik M, Bell C, Fitzwater T, et al. 1997. Isolation and characterization of 2′-fluoro-, 2′-amino-, and 2′-fluoro-/amino-modified RNA ligands to human IFN-gamma that inhibit receptor binding. J. Immunol. 159:259-67
98. Chambers CA, Kuhns MS, Egen JG, Allison JP. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19: 565-94
99. Santulli-Marotto S, Nair SK, Rusconi C, et al. 2003. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 63:7483-89
100. Nair SK, Heiser A, Boczkowski D, et al. 2000. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 6:1011-17